Detail Article

Informations générales (source: ClinicalTrials.gov)

Numéro NCT

NCT03800212 Statut inconnu

Titre

Study of Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma (AMPULLOMA)

Type

Observational

Pathologie

Adénocarcinome

Phase

Promoteur

Federation Francophone de Cancerologie Digestive (Voir sur ClinicalTrials)

Date de début

juillet 2017

Date de fin

décembre 2022

Dernière mise à jour

29 juin 2024

Résumé

A Vater's ampulloma is a rare digestive tumour which accounts for under 1% of all digestive tumours. The only curative treatment is complete excision (surgical or endoscopic) of the lesions which is possible in 80% of cases , with or without adjuvant treatment. The reference radical treatment is cephalic duodenopancreatectomy (CDP). The indication for adjuvant treatment is still debated: in view of the aggressive nature of the disease and the high recurrence rate, it would appear appropriate to offer adjuvant treatment, although several studies have failed to find any benefit on survival with post-operative radio-chemotherapy, the most widely studied treatment at present, compared to excision alone. At present there are no phase II studies specifically examining medical treatment of degenerated, inoperable Vater's ampullomas. Some groups propose chemotherapies with 5-FU or gemcitabine, analogous to the treatments used for intestinal, pancreatic or biliary tumours, although neither one has been shown to date to be superior to the other, nor have decision-making criteria been clearly established.In conclusion, a national cohort study is proposed to undertake a prospective analysis of the outcome of all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy). The treatment methods will be left to the free choice of the investigator and all patients may be included, regardless of stage of their disease. In this study, freezing of tumour fragments is encouraged, as this cohort will be supplemented by a later biological study. In order to recruit sufficient patient numbers, the study will be based on participation of the cooperative groups involved in the management of digestive cancers.

Détail

Voir le détail A Vater's ampulloma is a rare digestive tumour which accounts for under 1% of all digestive tumours. In terms of incidence, it is the 3rd most common biliary tract tumour after gallbladder cancer and common bile duct cancer. The incidence of ampullary adenocarcinoma is not well known although it is estimated to be around 0.49 per 100,000 people. The known risk factors are familial adenomatous polyposis (FAP) and Gardner's syndrome, HNPCC (Hereditary Non-Polyposis Colorectal Cancer) syndrome, Peutz-Jeghers syndrome, Crohn's disease and coeliac disease. Except in its highly localised forms, ampulla of Vater carcinoma carries a poor prognosis. It is a highly lymphophilic disease which commonly metastasises, particularly to the lymph nodes and liver. The prognosis is however considerably better than that of pancreatic adenocarcinoma. In one study which compared 71 ampullomas with 144 adenocarcinomas of pancreatic head, the 5-year survival was 60% for the ampullary carcinomas compared to 20% for pancreatic adenocarcinomas. More generally, the 5-year survival rate in the literature is between 40-60% and, depending on the study, 10-year survival is approximately 38% . The only curative treatment is complete excision (surgical or endoscopic) of the lesions which is possible in 80% of cases , with or without adjuvant treatment. The reference radical treatment is cephalic duodenopancreatectomy (CDP). The 5-year survival rate in cases of adenocarcinoma excised by CPD is in the region of 50%, rising to 60-70% if no lymph node invasion is present, compared to 30% when lymph nodes are invaded and median survival is approximately 4.5 years . The indication for adjuvant treatment is still debated: in view of the aggressive nature of the disease and the high recurrence rate, it would appear appropriate to offer adjuvant treatment, although several studies have failed to find any benefit on survival with post-operative radio-chemotherapy, the most widely studied treatment at present, compared to excision alone . There is only one single randomised study comparing these two forms of management, which shows no benefit in terms of 2 and 5-year survival, although only a small number of patients had an ampullary tumour in this study . The conclusions of several retrospective studies are more subtle, showing results in favour of adjuvant treatment in patients with lymph node disease or a large tumour (T3/T4) . Some groups have tested the merits of peroperative irradiation. It would appear that this technique does not improve survival, although data on this subject are extremely patchy . Administration of exclusive adjuvant chemotherapy has been examined in a single randomised study. In this phase III study (ESPAC 3), median overall survival of patients who received adjuvant chemotherapy with FUFOL Mayo for 6 months (n=101) or gemcitabine (n=98) was not significantly improved compared to survival in patients undergoing surgery and not receiving complementary treatment (57.1 versus 43 months, HR= 0.85, p=0.32). A subgroup analysis suggested that the benefit of chemotherapy could be greater in the subgroup of patients with RO resection (p= 0.057, 91% of cases). Mean survival in patients suffering inoperable tumours is between 9 and 20.4 months depending on the study . It should be noted however that most of these studies have included tumours other than ampullomas (particularly small bowel adenocarcinomas), making it more difficult to interpret these results, and also that many are old results dating from before the era of modern chemotherapies. At present there are no phase II studies specifically examining medical treatment of degenerated, inoperable Vater's ampullomas. Some groups propose chemotherapies with 5-FU or gemcitabine, analogous to the treatments used for intestinal, pancreatic or biliary tumours, although neither one has been shown to date to be superior to the other, nor have decision-making criteria been clearly established. One phase II study published in 2009 proposed CAPOX as the reference treatment in light of the promising results obtained. Patients suffering from ampullary cancer in this study however were combined with patients who were suffering from small bowel adenocarcinoma. In conclusion, a national cohort study is proposed to undertake a prospective analysis of the outcome of all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy). The treatment methods will be left to the free choice of the investigator and all patients may be included, regardless of stage of their disease. In this study, freezing of tumour fragments is encouraged, as this cohort will be supplemented by a later biological study. In order to recruit sufficient patient numbers, the study will be based on participation of the cooperative groups involved in the management of digestive cancers. Fermer le détail

Etablissements

Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
AP-HP - Hôpital Avicenne	THOMAS APARICIO	En recrutement IDF	Contact (sur clinicalTrials)
AP-HP - Hôpital Cochin	ROMAIN CORIAT	En recrutement IDF	Contact (sur clinicalTrials)
AP-HP - Hôpital Europeen Georges Pompidou	ORIANNE COLUSSI	En recrutement IDF	Contact (sur clinicalTrials)
AP-HP - Hôpital La Pitié-Salpêtrière	JEAN BAPTISTE BACHET	En recrutement IDF	Contact (sur clinicalTrials)
CENTRE HOSPITALIER SUD FRANCILIEN	SAMY LOUAFI	En recrutement IDF	Contact (sur clinicalTrials)
GROUPE HOSPITALIER NORD ESSONNE	YOUNES ZEKRI	En recrutement IDF	Contact (sur clinicalTrials)
Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Ch Annecy Genevois - Annecy - France	ROMAN COMBES	En recrutement	Contact (sur clinicalTrials)
Ch Bretagne Atlantique - Vannes - France	DENIS GRASSET	En recrutement	Contact (sur clinicalTrials)
Ch Cornouaille - Quimper - France	KARINE BIDEAU	En recrutement	Contact (sur clinicalTrials)
Ch Cote Basque - Bayonne - France	FRANCK AUDEMAR	En recrutement	Contact (sur clinicalTrials)
Ch D'Abbeville - Abbeville - France	JOEL BUTEL	En recrutement	Contact (sur clinicalTrials)
CH MACON - Mâcon - France	MARIE MARTIN BELLECOSTE	En recrutement	Contact (sur clinicalTrials)
Ch Saint Jean - Perpignan - France	FAIZA KHEMISSA AKOUZ	En recrutement	Contact (sur clinicalTrials)
Chr Orleans - Orléans - France	BRAHIM OUAHRANI	En recrutement	Contact (sur clinicalTrials)
Chu Caremeau - Nîmes - France	CLAIRE PHILIPPE	En recrutement	Contact (sur clinicalTrials)
Chu Claude Huriez - Lille - France	christophe MARIETTE	En recrutement	Contact (sur clinicalTrials)
Chu Estaing - Clermont-Ferrand - France	DENIS PEZET	En recrutement	Contact (sur clinicalTrials)
Chu Francois Mitterrand - Dijon - France	SYLVAIN MANFREDI	En recrutement	Contact (sur clinicalTrials)
CHU Hôpital de la Milétrie - Poitiers - France	David TOUGERON	En recrutement	Contact (sur clinicalTrials)
Chu Hotel Dieu - Angers - France	NATHALIE BAIZE	En recrutement	Contact (sur clinicalTrials)
Chu La Croix Rousse - Lyon - France	MARIELLE GUILLET	En recrutement	Contact (sur clinicalTrials)
Chu Saint Andre - Bordeaux - France	CHABRUN	En recrutement	Contact (sur clinicalTrials)
CLINIQUE - Strasbourg - France	YOUSSEF TAZI	En recrutement	Contact (sur clinicalTrials)
Clinique Champeau - Béziers - France	MICHAEL HUMMELSBERGER	En recrutement	Contact (sur clinicalTrials)
Hcl Edouard Herriot - Lyon - France	MUSTAPHA ADHAM	En recrutement	Contact (sur clinicalTrials)
Hcl Pierre Benite - Lyon - France	OLIVIER GLEHEN	En recrutement	Contact (sur clinicalTrials)
Hopital de La Timone - Marseille - France	MARINE BARRAUD BLANC	En recrutement	Contact (sur clinicalTrials)
Hôpital Dupuytren - Limoges - France	STEPHANE BOUVIER	En recrutement	Contact (sur clinicalTrials)
Hopitaux Civils de Colmar - Colmar - France	LAURIANNE PLASTARAS	En recrutement	Contact (sur clinicalTrials)
Polyclinique Bordeaux Nord Aquitaine - Bordeaux - France	BALHADERE	En recrutement	Contact (sur clinicalTrials)
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CH - Reims - France	Olivier BOUCHE	En recrutement	Contact (sur clinicalTrials)
Ch de Meaux - Meaux - France	CHRISTOPHE LOCHER	En recrutement	Contact (sur clinicalTrials)
Ch Saint Malo - Saint-Malo - France	ROMAIN DESGRIPPES	En recrutement	Contact (sur clinicalTrials)
Chd Vendee - La Roche-sur-Yon - France	MORGAN AMIL	En recrutement	Contact (sur clinicalTrials)
Hopital Saint Joseph - Marseille - France	HERVE PERRIER	En recrutement	Contact (sur clinicalTrials)
Le Kremlin Bicetre - Le Kremlin-Bicêtre - France	Stéphane BENOIST	En recrutement	Contact (sur clinicalTrials)

Critères

Genre

Tous

Nombre d'inclusion

Critère d'inclusion

Inclusion Criteria:

- Patients aged 18 years and older.

- Histologically-proven adenocarcinoma of the ampulla of Vater which is operable or
with locoregional or metastatic recurrence after excision less than 6 months
previously.

Critère de non inclusion

- Patients who cannot be followed up regularly for psychological, social, family or
geographical reasons.

- Non-ampullary tumours.

- Non-adenocarcinomatous ampullary tumours.

- Ampullary adenocarcinomas which are metastatic or locally advanced from the outset
and inoperable.

NCT03800212 - Study of Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma (AMPULLOMA)

Informations générales
Etablissements
Critères
Accès à la fiche NCT

Retour en haut